Crude Oil Down 3%; Chicago Fed National Activity Index Falls In October
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 25 2024
0mins
Should l Buy BBIO?
Source: Benzinga
U.S. Stock Market Performance: U.S. stocks mostly rose, with the Dow Jones gaining over 250 points, while real estate shares increased by 1.5%. However, energy shares fell by 0.7%, and notable declines were seen in Cassava Sciences and Oncternal Therapeutics.
Global Market Trends: European markets showed gains, with the eurozone's STOXX 600 up 0.16%, while Asian markets closed mixed. The Chicago Fed National Activity Index fell to -0.40 in October, indicating economic slowdown.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BBIO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BBIO
Wall Street analysts forecast BBIO stock price to rise
13 Analyst Rating
13 Buy
0 Hold
0 Sell
Strong Buy
Current: 67.610
Low
85.00
Averages
98.50
High
157.00
Current: 67.610
Low
85.00
Averages
98.50
High
157.00
About BBIO
BridgeBio Pharma, Inc. is a biopharmaceutical company. It discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases. Its pipeline of development programs ranges from early science to advanced clinical trials, which includes Attruby, an oral small molecule near-complete transthyretin (TTR) stabilizer, for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); Beyonttra for the treatment of TTR Amyloidosis; Low-dose Infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI) for the treatment of children with achondroplasia and hypochondroplasia; Encaleret, an oral small molecule antagonist of the calcium sensing receptor (CaSR) that it is developing for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1), and BBP-418, for the treatment of Limb Girdle Muscular Dystrophy Type 2I. It also conducting a Phase 1/2 study (CANaspire) for BBP-812 for Canavan disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
BridgeBio Pharma Q4 2025 Earnings Call Insights
- Strong Financial Performance: BridgeBio reported total revenues of $154.2 million in Q4 2025, with net product revenue from Attruby reaching $146.2 million, a significant increase from $5.9 million in the same period last year, indicating robust market performance and product acceptance.
- Optimistic Future Outlook: Management expects to achieve over $600 million in profit by 2028, primarily driven by four late-stage Phase III assets, signaling a transition to positive cash flow and enhancing future financial stability.
- Product Launch Readiness: CEO Kumar emphasized that market launches for encaleret and BBP-418 are anticipated in late 2026 or early 2027, reflecting proactive preparations for new product introductions aimed at further expanding market share.
- Competitive Risk Management: Despite stock volatility due to tafamidis IP issues, management remains confident in Attruby's market positioning, highlighting that differentiated clinical data will be a key advantage in future competition.
See More
BridgeBio (BBIO) Q4 2025 Earnings Call Transcript
See More
BridgeBio Pharma Q4 Earnings Beat Expectations with Strong Revenue Growth
- Earnings Report: BridgeBio Pharma reported a Q4 GAAP EPS of -$1.00, missing expectations by $0.33, indicating ongoing challenges in profitability despite revenue growth.
- Revenue Surge: The company achieved Q4 revenue of $154.2M, reflecting a staggering year-over-year increase of 2513.6%, surpassing market expectations by $5.13M, which highlights strong demand for its products, particularly in pediatric achondroplasia treatments.
- Clinical Trial Success: BridgeBio announced positive results from its Phase 3 PROPEL 3 trial for Infigratinib in children with achondroplasia, potentially providing robust support for future revenue growth.
- Financing Activity: The company successfully priced a $550M convertible bond offering, enhancing its liquidity and providing financial backing for ongoing R&D and market expansion efforts.
See More
BridgeBio Pharma to Announce Q4 Earnings on February 24
- Earnings Announcement: BridgeBio Pharma is set to release its Q4 earnings on February 24, with consensus EPS estimates at -$0.62 and revenue projections at $149.07 million, a significant increase from $5.9 million in Q4 2024, indicating potential revenue growth for the company.
- Positive Clinical Results: The company reported positive Phase 3 PROPEL 3 results for Infigratinib in treating achondroplasia in children, which not only boosts confidence in its product pipeline but also enhances its competitive position in the relevant market.
- Convertible Bond Offering: BridgeBio plans to issue a $550 million convertible bond, a strategic move that will provide essential funding to support its R&D initiatives and market expansion, thereby enhancing its financial flexibility.
- Market Reaction: Following the success in late-stage trials, BridgeBio's stock has risen, reflecting increased investor confidence in its treatment options and indicating a positive outlook for the company's future growth prospects.
See More
BridgeBio Pharma to Participate in Multiple Healthcare Investor Conferences
- Conference Participation: BridgeBio Pharma will participate in three healthcare investor conferences on March 2, 10, and 11, showcasing its latest advancements in drug development for genetic conditions, which is expected to attract investor interest and enhance the company's visibility.
- Live Webcast Access: The company will provide live streaming and replays of the presentations on its website, ensuring investors can access real-time information, thereby enhancing transparency and fostering interaction with investors, which further solidifies its market position in biopharmaceuticals.
- Mission Statement: BridgeBio focuses on developing transformative medicines for genetic conditions, aiming to bridge the market gap in drug development for small patient populations, highlighting its strategic importance in addressing unmet patient needs.
- Operational Model Advantage: The company employs a decentralized hub-and-spoke model designed to enhance the speed and precision of drug development, increasing its flexibility and responsiveness in the competitive biopharmaceutical market.
See More
Worst Performing Large-Cap Stocks Last Week
- GPC Earnings Miss: Genuine Parts Company (NYSE:GPC) saw a 19.51% drop this week after reporting disappointing fourth-quarter results and issuing FY26 EPS guidance below estimates, prompting multiple analysts to lower their price targets, indicating market concerns over its future profitability.
- FLUT Earnings Awaited: Flutter Entertainment plc (NYSE:FLUT) decreased by 11.86% this week as the company announced it will release its fourth quarter and full year 2025 financial results after market close on February 26, leading investors to adopt a cautious stance ahead of the earnings report, which may impact stock performance.
- OKTA Price Target Cuts: Okta, Inc. (NASDAQ:OKTA) fell 12.86% this week after several firms lowered their price targets, reflecting diminished market confidence in its growth potential and possibly prompting investors to reassess its investment value.
- TEAM Executive Change: Atlassian Corporation (NASDAQ:TEAM) decreased by 5.33% this week following the announcement of James Chuong as the new Chief Financial Officer effective March 30, 2026; while executive changes may bring new strategic directions, they failed to boost the stock price in the short term.
See More
BridgeBio Pharma Q4 2025 Earnings Call Insights
- Strong Financial Performance: BridgeBio reported total revenues of $154.2 million in Q4 2025, with net product revenue from Attruby reaching $146.2 million, a significant increase from $5.9 million in the same period last year, indicating robust market performance and product acceptance.
- Optimistic Future Outlook: Management expects to achieve over $600 million in profit by 2028, primarily driven by four late-stage Phase III assets, signaling a transition to positive cash flow and enhancing future financial stability.
- Product Launch Readiness: CEO Kumar emphasized that market launches for encaleret and BBP-418 are anticipated in late 2026 or early 2027, reflecting proactive preparations for new product introductions aimed at further expanding market share.
- Competitive Risk Management: Despite stock volatility due to tafamidis IP issues, management remains confident in Attruby's market positioning, highlighting that differentiated clinical data will be a key advantage in future competition.
See More
BridgeBio (BBIO) Q4 2025 Earnings Call Transcript
See More
BridgeBio Pharma Q4 Earnings Beat Expectations with Strong Revenue Growth
- Earnings Report: BridgeBio Pharma reported a Q4 GAAP EPS of -$1.00, missing expectations by $0.33, indicating ongoing challenges in profitability despite revenue growth.
- Revenue Surge: The company achieved Q4 revenue of $154.2M, reflecting a staggering year-over-year increase of 2513.6%, surpassing market expectations by $5.13M, which highlights strong demand for its products, particularly in pediatric achondroplasia treatments.
- Clinical Trial Success: BridgeBio announced positive results from its Phase 3 PROPEL 3 trial for Infigratinib in children with achondroplasia, potentially providing robust support for future revenue growth.
- Financing Activity: The company successfully priced a $550M convertible bond offering, enhancing its liquidity and providing financial backing for ongoing R&D and market expansion efforts.
See More
BridgeBio Pharma to Announce Q4 Earnings on February 24
- Earnings Announcement: BridgeBio Pharma is set to release its Q4 earnings on February 24, with consensus EPS estimates at -$0.62 and revenue projections at $149.07 million, a significant increase from $5.9 million in Q4 2024, indicating potential revenue growth for the company.
- Positive Clinical Results: The company reported positive Phase 3 PROPEL 3 results for Infigratinib in treating achondroplasia in children, which not only boosts confidence in its product pipeline but also enhances its competitive position in the relevant market.
- Convertible Bond Offering: BridgeBio plans to issue a $550 million convertible bond, a strategic move that will provide essential funding to support its R&D initiatives and market expansion, thereby enhancing its financial flexibility.
- Market Reaction: Following the success in late-stage trials, BridgeBio's stock has risen, reflecting increased investor confidence in its treatment options and indicating a positive outlook for the company's future growth prospects.
See More
BridgeBio Pharma to Participate in Multiple Healthcare Investor Conferences
- Conference Participation: BridgeBio Pharma will participate in three healthcare investor conferences on March 2, 10, and 11, showcasing its latest advancements in drug development for genetic conditions, which is expected to attract investor interest and enhance the company's visibility.
- Live Webcast Access: The company will provide live streaming and replays of the presentations on its website, ensuring investors can access real-time information, thereby enhancing transparency and fostering interaction with investors, which further solidifies its market position in biopharmaceuticals.
- Mission Statement: BridgeBio focuses on developing transformative medicines for genetic conditions, aiming to bridge the market gap in drug development for small patient populations, highlighting its strategic importance in addressing unmet patient needs.
- Operational Model Advantage: The company employs a decentralized hub-and-spoke model designed to enhance the speed and precision of drug development, increasing its flexibility and responsiveness in the competitive biopharmaceutical market.
See More
Worst Performing Large-Cap Stocks Last Week
- GPC Earnings Miss: Genuine Parts Company (NYSE:GPC) saw a 19.51% drop this week after reporting disappointing fourth-quarter results and issuing FY26 EPS guidance below estimates, prompting multiple analysts to lower their price targets, indicating market concerns over its future profitability.
- FLUT Earnings Awaited: Flutter Entertainment plc (NYSE:FLUT) decreased by 11.86% this week as the company announced it will release its fourth quarter and full year 2025 financial results after market close on February 26, leading investors to adopt a cautious stance ahead of the earnings report, which may impact stock performance.
- OKTA Price Target Cuts: Okta, Inc. (NASDAQ:OKTA) fell 12.86% this week after several firms lowered their price targets, reflecting diminished market confidence in its growth potential and possibly prompting investors to reassess its investment value.
- TEAM Executive Change: Atlassian Corporation (NASDAQ:TEAM) decreased by 5.33% this week following the announcement of James Chuong as the new Chief Financial Officer effective March 30, 2026; while executive changes may bring new strategic directions, they failed to boost the stock price in the short term.
See More
